TF
AZN icon

TIAA FSB’s AstraZeneca AZN Stock Holding History

TIAA FSB’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$1.04M Sell
7,301
-203
-3% -$29.9K ﹤0.01% 311
2023
Q1 		$1.04M Buy
7,504
+129
+2% +$17.4K ﹤0.01% 312
2022
Q4 		$1M Sell
7,375
-208
-3% -$26.1K ﹤0.01% 309
2022
Q3 		$832K Sell
7,583
-674
-8% -$85.5K ﹤0.01% 331
2022
Q2 		$1.09M Sell
8,257
-1,116
-12% -$146K ﹤0.01% 311
2022
Q1 		$1.03M Sell
9,373
-2,514
-21% -$301K ﹤0.01% 308
2021
Q4 		$1.19M Sell
11,887
-708
-6% -$83.3K ﹤0.01% 297
2021
Q3 		$1.51M Buy
12,595
+1,735
+16% +$202K 0.01% 283
2021
Q2 		$1.3M Sell
10,860
-378
-3% -$41.5K ﹤0.01% 297
2021
Q1 		$1.12M Sell
11,238
-2,571
-19% -$258K ﹤0.01% 297
2020
Q4 		$1.38M Sell
13,809
-1,053
-7% -$112K 0.01% 272
2020
Q3 		$1.63M Sell
14,862
-2,523
-15% -$281K 0.01% 230
2020
Q2 		$1.84M Buy
17,385
+6,459
+59% +$667K 0.01% 225
2020
Q1 		$977K Sell
10,926
-790
-7% -$74.4K 0.01% 229
2019
Q4 		$1.17M Sell
11,716
-2,826
-19% -$266K 0.01% 254
2019
Q3 		$1.3M Sell
14,542
-1,339
-8% -$116K 0.01% 241
2019
Q2 		$1.31M Sell
15,881
-214
-1% -$16.8K 0.01% 234
2019
Q1 		$1.3M Sell
16,095
-133,895
-89% -$10.6M 0.01% 241
2018
Q4 		$11.4M Sell
149,990
-35,484
-19% -$2.77M 0.06% 97
2018
Q3 		$14.7M Sell
185,474
-15,244
-8% -$1.15M 0.08% 89
2018
Q2 		$14.1M Buy
200,718
+73,716
+58% +$5.3M 0.08% 86
2018
Q1 		$8.88M Buy
127,002
+113,458
+838% +$7.86M 0.05% 112
2017
Q4 		$940K Buy
13,544
+846
+7% +$57K 0.01% 315
2017
Q3 		$860K Buy
12,698
+1,446
+13% +$91.4K 0.01% 323
2017
Q2 		$767K Buy
+11,252
New +$735K 0.01% 319

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TIAA FSB's AZN Position: Q2 2023 in Review

TIAA FSB reduced its AstraZeneca (AZN) stake by 2.7% in Q2 2023, selling an estimated $29.9K and leaving 7,301 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #311.

TIAA FSB first reported a position in AZN in Q2 2017 and has held it in 25 quarters since. The position peaked at $14.7M in Q3 2018. 1,091 funds tracked by Wall St. Rank hold AZN as of Q2 2023.

  • TIAA FSB held 7,301 shares of AstraZeneca worth $1.04M as of Q2 2023.
  • TIAA FSB sold 203 AstraZeneca shares in Q2 2023, an estimated $29.9K.
  • AstraZeneca made up ﹤0.01% of TIAA FSB's portfolio in Q2 2023, its #311 holding.
  • TIAA FSB first reported a position in AstraZeneca in Q2 2017 and has held it in 25 quarters since.
  • TIAA FSB's AstraZeneca position peaked at $14.7M in Q3 2018.
  • 1,091 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2023.

Based on TIAA FSB's 13F filing for Q2 2023, filed 31 Jul 2023.